On September 5, the list of finalists of the 12th China Innovation and Entrepreneurship Competition was announced, and Shenzhen Cell Valley successfully qualified for the 12th China Innovation and Entrepreneurship Competition. China Innovation and Entrepreneurship Competition is a national innovation and entrepreneurship competition with the highest specifications, the largest scale, the most extensive influence and the most authoritative under the joint guidance of the Ministry of Science and Technology, the Ministry of Education, the Ministry of Finance, the All-China Federation of Industry and Commerce and the CAC. After fierce competition, a total of 1,494 enterprises were shortlisted in the 12th China Innovation and Entrepreneurship Competition national competition, of which 1,096 were growth groups, and 15 were selected in the growth group of biomedical enterprises in Shenzhen Competition area. Sun Rui, our senior research and development scientist, highlighted the fierce encirkment.Shenzhen Cell Valley became the only cell and gene therapy enterprise in Shenzhen to qualify for the national competition.

Innovation and entrepreneurship has always been an important engine to promote economic and social development. As the only CRO/CDMO one-stop outsourcing service provider in China that has mastered industrial retrovirus vector technology (PackRV-SS and other systems), Shenzhen Cell Valley will continue to fully leverage the absolute advantages of industrial retrovirus vector production in reducing costs and industrial production. In combination with the practical experience of talent training in professional fields, we will fully combine scientific research and achievement transformation, guide talent training through work practice, drive the development of cell therapy industry through talent training, build a talent training base for cell therapy drug research and development and industrialization, and solve the core challenge of cell therapy commercialization - industrial production and manufacturing of viral vectors and talent shortage. Shorten the cycle of Chinese local cell therapy drugs from new drug development to drug listing, build a cell and gene therapy enterprise incubation base, lay a solid foundation for commercialization, and continue to contribute to the high-quality development of cell and gene therapy in Shenzhen and even the whole country.